Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9584688 | 0.93 | CYP1A2 (0.61) | CYP1A2CYP2D6MAPK1MEN1ALDH1A1 | |
| SCHEMBL10814219 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPK1MEN1ALDH1A1 | |
| SCHEMBL9583644 | 0.78 | CYP1A2 (0.45) | CYP1A2CYP2D6MAPK1MEN1ALDH1A1 | |
| SCHEMBL9583917 | 0.77 | CYP1A2 (0.50) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL9584499 | 0.75 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPK1ALDH1A1LMNA | |
| SCHEMBL10405635 | 0.75 | BLM (0.56) | CYP1A2CYP2D6MAPK1MEN1ALDH1A1 | |
| SCHEMBL9583977 | 0.74 | CYP1A2 (0.40) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL10816715 | 0.74 | CYP2D6 (0.45) | CYP1A2CYP2D6MAPK1CYP3A4 | |
| SCHEMBL6903378 | 0.74 | CYP1A2 (0.51) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL4093935 | 0.73 | ADORA2A (0.64) | MEN1ALDH1A1LMNACYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897759-B2 | Metabolically stable puromycin analogs | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090069556-A1 | METABOLICALLY STABLE PUROMYCIN ANALOGS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069556-A1 | METABOLICALLY STABLE PUROMYCIN ANALOGS | PDF, NPEPPS, RNMT | CYP1A2 3469/4885CYP2D6 1123/4885MAPK1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.